ADA2 and ischemic stroke: Some authors recommend treatment initiation when biallelic ADA2 variants coincide with the absence of catalytic ADA2 activity in both symptomatic and asymptomatic patients, to reduce the risk of ischemic stroke and prevent severe neurological complications (8, 11, 14, 16, 20).